Literature DB >> 15558523

Coronary artery calcification in patients with CRF not undergoing dialysis.

Domenico Russo1, Giuseppe Palmiero, Antonietta P De Blasio, Mario M Balletta, Vittorio E Andreucci.   

Abstract

BACKGROUND: Coronary artery calcification (CAC) correlates with the extent of coronary atherosclerosis and, consequently, with an increased risk for cardiovascular events. CAC is more frequent in uremic patients than in the general population. Nearly all data about CAC relate to patients on dialysis therapy. This study evaluates the prevalence and extent of CAC in patients with chronic renal failure (CRF) not yet on dialysis therapy.
METHODS: Consecutive outpatients with CRF not on dialysis therapy were enrolled and compared with controls (ie, healthy volunteers and patients with essential hypertension with normal renal function). Patients and controls were asymptomatic and had no previous history of myocardial infarction, coronary bypass surgery, or angioplasty. Patients with diabetes were excluded. Clinical characteristics, biochemical test results (included homocysteinemia and C-reactive protein level), and serum concentrations of calcium, phosphorus, and intact parathyroid hormone (iPTH) were evaluated in patients and controls. CACs were searched for and scored by means of spiral computed tomography (CT). To assess the CAC progression rate, spiral CT was repeated in some patients.
RESULTS: Eighty-five patients and 55 controls were studied. Patients were aged 52 +/- 13 years and had a CRF duration of 6.3 +/- 5.6 years, glomerular filtration rate of 33.0 +/- 16.0 mL/min (0.55 +/- 0.27 mL/s), serum calcium level of 9.5 +/- 0.5 mg/dL (2.37 +/- 0.12 mmol/L), serum phosphorus level of 4.1 +/- 0.9 mg/dL (1.32 +/- 0.29 mmol/L), and serum iPTH level of 143 +/- 121 pg/mL (ng/L). CAC was found in 40% of patients and 13% of controls; calcification scores were 422 +/- 634 in patients and 43.9 +/- 33 in controls. Only age ( P < 0.001) was a predictor of CAC. In patients with a repeated score performed (after a mean of 7.9 months), calcification scores increased (from 383 +/- 627 to 682 +/- 890) in 8 of 10 patients.
CONCLUSION: CAC is already present in the early phase of CRF; the prevalence is greater in patients with CRF than in controls, but less than that reported in dialysis patients. Serum concentrations of calcium, phosphorus, iPTH, and inflammation markers do not predict the appearance or progression of CAC.

Entities:  

Mesh:

Year:  2004        PMID: 15558523     DOI: 10.1053/j.ajkd.2004.07.022

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  94 in total

1.  Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention.

Authors:  Patrik Htun; Suzanne Fateh-Moghadam; Christian Bischofs; Winston Banya; Karin Müller; Boris Bigalke; Konstantinos Stellos; Andreas E May; Marcus Flather; Meinrad Gawaz; Tobias Geisler
Journal:  J Am Soc Nephrol       Date:  2011-01-27       Impact factor: 10.121

2.  Phylloquinone and vitamin D status: associations with incident chronic kidney disease in the Framingham Offspring cohort.

Authors:  Conall M O'Seaghdha; Shih-Jen Hwang; Rachel Holden; Sarah L Booth; Caroline S Fox
Journal:  Am J Nephrol       Date:  2012-06-20       Impact factor: 3.754

3.  Impact of circulating cathepsin K on the coronary calcification and the clinical outcome in chronic kidney disease patients.

Authors:  Yusuke Izumi; Mutsuharu Hayashi; Ryota Morimoto; Xian Wu Cheng; Hongxian Wu; Hideki Ishii; Yoshinari Yasuda; Daiji Yoshikawa; Hideo Izawa; Seiichi Matsuo; Yutaka Oiso; Toyoaki Murohara
Journal:  Heart Vessels       Date:  2014-08-24       Impact factor: 2.037

4.  Coronary artery calcium screening: current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging.

Authors:  Matthijs Oudkerk; Arthur E Stillman; Sandra S Halliburton; Willi A Kalender; Stefan Möhlenkamp; Cynthia H McCollough; Rozemarijn Vliegenthart; Leslee J Shaw; William Stanford; Allen J Taylor; Peter M A van Ooijen; Lewis Wexler; Paolo Raggi
Journal:  Eur Radiol       Date:  2008-07-24       Impact factor: 5.315

5.  Coronary artery calcification scores in patients with chronic kidney disease prior to dialysis: reliability as a trial outcome measure.

Authors:  Katherine A Barraclough; Lesley A Stevens; Lee Er; Debbie Rosenbaum; Jacqueline Brown; Pari Tiwari; Adeera Levin
Journal:  Nephrol Dial Transplant       Date:  2008-05-01       Impact factor: 5.992

6.  Coronary artery calcification, ADMA, and insulin resistance in CKD patients.

Authors:  Shuzo Kobayashi; Machiko Oka; Kyoko Maesato; Ryota Ikee; Tsutomu Mano; Moriya Hidekazu; Takayasu Ohtake
Journal:  Clin J Am Soc Nephrol       Date:  2008-06-18       Impact factor: 8.237

7.  Impact of cardiovascular calcification in nondialyzed patients after 24 months of follow-up.

Authors:  Renato Watanabe; Marcelo M Lemos; Silvia R Manfredi; Sérgio A Draibe; Maria Eugênia F Canziani
Journal:  Clin J Am Soc Nephrol       Date:  2009-12-03       Impact factor: 8.237

8.  Outcomes associated with serum calcium level in men with non-dialysis-dependent chronic kidney disease.

Authors:  Csaba P Kovesdy; Olga Kuchmak; Jun L Lu; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 8.237

9.  Coronary calcification in patients with chronic kidney disease and coronary artery disease.

Authors:  Satoko Nakamura; Hatsue Ishibashi-Ueda; Sinichiro Niizuma; Fumiki Yoshihara; Takeshi Horio; Yuhei Kawano
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 8.237

10.  No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease.

Authors:  Rajnish Mehrotra; Carmen A Peralta; Shu-Cheng Chen; Suying Li; Michael Sachs; Anuja Shah; Keith Norris; Georges Saab; Adam Whaley-Connell; Bryan Kestenbaum; Peter A McCullough
Journal:  Kidney Int       Date:  2013-04-24       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.